SCHEMBL16697151

SCHEMBL16697151

CC(C)(C(=O)ONC(=N)c1ccc2c(c1)OCO2)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.47
NPC1 O15118 7/20 0.47
PKM P14618 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPK1 P28482 1/20 0.46
CTNNB1 P35222 1/20 0.45
WNT3A P56704 1/20 0.45
PTGS2 P35354 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16697795 0.91 RAB9A (0.47) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16697152 0.79 RAB9A (0.57) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16697149 0.79 RAB9A (0.57) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16698353 0.73 RAB9A (0.69) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16698330 0.73 CTNNB1 (0.60) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16697797 0.72 RAB9A (0.57) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16697793 0.72 RAB9A (0.57) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16697358 0.72 RAB9A (0.49) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16701197 0.71 NPC1 (0.49) RAB9ANPC1PKMSMN1; SMN2ALDH1A1
SCHEMBL16697641 0.71 CTNNB1 (0.50) RAB9ANPC1PKMSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150133495-A1 Substituted Acyloxyamidines as HCV NS3/4A Inhibitors VIROCURA THERAPEUTICS INC (CA) 2015-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133495-A1 Substituted Acyloxyamidines as HCV NS3/4A Inhibitors EIF2AK2, GTF3C4, GTF3C1 RAB9A 465/4885NPC1 922/4885PKM 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.